Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2008 08:23 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results

CAMBRIDGE, Mass., May 5, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today provided a research and development...
April 28, 2008 12:34 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Conference Call Discussing R&D Progress and First Quarter 2008 Results

CAMBRIDGE, Mass., April 28, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Infinity management...
April 25, 2008 09:38 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At Morgan Stanley Global Healthcare Unplugged Conference

CAMBRIDGE, Mass., April 25, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven. H....
April 15, 2008 17:42 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity's Hedgehog Antagonist Delays Tumor Growth Following Chemotherapy in Preclinical Model of Small Cell Lung Cancer; Data Presented At AACR

CAMBRIDGE, Mass., April 15, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical data from a model of small cell lung cancer (SCLC) show that...
April 15, 2008 17:01 ET | Source: Infinity Pharmaceuticals, Inc.

Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance Presented by Infinity and MedImmune At AACR

SAN DIEGO, April 15, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune today announced that preclinical studies evaluating lead drug candidate retaspimycin...
April 13, 2008 17:30 ET | Source: Infinity Pharmaceuticals, Inc.

New Preclinical Data Show Significant Anti-Tumor Activity Associated With Infinity's Hedgehog Antagonist IPI-926

SAN DIEGO, Calif. and CAMBRIDGE, Mass., April 13, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical studies evaluating IPI-926, Infinity's novel...
April 07, 2008 08:46 ET | Source: Infinity Pharmaceuticals, Inc.

New Data On Infinity's Lead Anti-Cancer Candidates to be Presented At AACR

CAMBRIDGE, Mass., April 7, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from...
March 11, 2008 12:49 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At Cowen Annual Health Care Conference

CAMBRIDGE, Mass., March 11, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman,...
February 13, 2008 17:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Highlights Broad Expansion of Hsp90 Clinical Program and Announces Fourth Quarter Financial Results

CAMBRIDGE, Mass., Feb. 13, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today provided a research and development...
February 12, 2008 08:29 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At Annual Roth OC Growth Stock Conference

CAMBRIDGE, Mass., Feb. 12, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey K. Tong,...